Catalyst Wire Dossier Catalyst Wire Dossier

Xbryk

denosumab · Samsung Bioepis NL B.V.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Xbryk, covering 2025-07-10 to 2025-07-10. Get the full timeline:

Most recent: EMA Authorised: Xbryk (denosumab) — Samsung Bioepis NL B.V.

See pricing